Screener
Guardant Health GH Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Product | ||||||
| Biopharma and data | $52.98M+16.8% | $54.01M+9.1% | $54.73M+17.6% | $56.02M+27.5% | $45.38M+20.7% | |
| Licensing and other | $2.14M+15.3% | $2.18M-15.0% | $1.95M-28.5% | $2.57M-15.3% | $1.86M-63.9% | |
| Oncology | $204.95M+36.1% | $189.95M+30.4% | $184.4M+30.6% | $158.69M+21.8% | $150.56M+19.7% | |
| Screening | $41.59M+633% | $35.13M+752% | $24.11M+2,304% | $14.81M— | $5.68M— | |
| Revenue by Geography | ||||||
| International | $17.04M+72.7% | $17.72M+73.4% | $15.76M+38.6% | $15.4M+68.9% | $9.86M-11.5% | |
| United States | $284.63M+47.0% | $263.55M+37.6% | $249.44M+38.5% | $216.68M+28.9% | $193.61M+23.0% |
FAQ
- How does Guardant Health break its business down?
- Guardant Health (GH) reports total revenue by product across 4 parts — Biopharma and data, Licensing and other, Oncology and Screening. Each is extracted from the segment footnotes and tracked over time.
- Where does Guardant Health's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Guardant Health's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
